The research-grade material supplied by Koi Peptides Canada is synthesized independently, is not equivalent to and is not a substitute for the clinical trial supply produced by Eli Lilly under its investigational new drug protocols, and is not a substitute for any future drug product that may receive marketing authorization from Health Canada or any comparable regulator
Muscle loss slows metabolism, which slows weight loss
Danuglipron: Developed by Pfizer and intended to keep blood glucose at healthy levels, this oral GLP-1 recently completed Phase 2 clinical trials for the treatment of type 2 diabetes and obesity
It controls how quickly you burn calories, store fat, and process food
Symptoms can include sweating, shaking, hunger, blurred vision, confusion, or unusual drowsiness
Both have clinical evidence supporting their use for nausea, independent of the retatrutide context